KPV peptide dosage: why no human dose exists and what animals received

No one knows what dose of KPV, if any, does anything in a person, because no one has measured it. FDA’s May 2026 review of KPV found no clinical studies, no human pharmacokinetic data (how a drug is absorbed and cleared) and no human exposure of any kind. The only numbers that exist come from animals and cells, and they are reported below for what they are. Nothing here is a recommendation. KPV is not FDA-approved and has no label, so no one can give you a dose with human evidence behind it.

What the animal and cell studies used

Some of these numbers are easier to read in plainer units. KPV free base weighs 342.43 g per mole, so 100 µM is about 34 mg per liter of drinking water, or 0.034 mg/mL. The study did not report how much each mouse drank, so the dose per kilogram is not known. A 0.1% cream is 1 mg of KPV per gram. The rabbit eye drops contained 30 to 300 µg per drop. These figures are not comparable to each other, let alone to anything a person might use.

Why these numbers do not become a human dose

There is nothing to scale from. FDA’s 2005 guidance on first-in-human dosing starts from a dose that formal toxicology studies have shown to cause no harm in animals, then builds in a large safety margin for a supervised trial. FDA’s 2026 review found no acute, repeat-dose, genotoxicity, reproductive or carcinogenicity studies of KPV. The starting point the method needs does not exist, so any human number built from these mouse studies would be invented, and we do not publish one.

The formulation was the point. The best-defined mouse doses were inside nanoparticles or conjugates engineered to release KPV in the colon. The 2010 study’s headline finding was that packaging cut the needed concentration 12,000-fold. A vial of plain KPV powder, injected under the skin or swallowed, is a different product, and the mouse data say nothing about how much of it reaches any tissue.

Route changes everything. The colitis studies dosed by mouth to treat the colon from the inside. The rabbit study put drops directly on the eye. FDA’s review notes that KPV passes poorly through intact human skin. An injection under the skin, a route promoted online, was not used in any of the studies above. FDA found websites promoting injectable, oral, topical and nasal spray KPV; no human study supports a dose for any of them.

Short, artificial disease models. The colitis was chemically induced over days. Human inflammatory bowel disease lasts years. No study measured what months of KPV exposure does to an animal, let alone a person.

How much, how often, and what about a missed dose?

There is no tested answer to any of these, and it is better to say so plainly than to borrow a schedule from a forum.

• How much per day: not established. The October 2026 HHS policy names forms and routes and sets no dose.
• How often and for how long: not established. The longest colitis course in the table above lasted about a week, in mice.
• Time of day, with or without food: never studied in people.
• Missed doses: a missed-dose rule comes from a label, and KPV has no label.
• What happens at each step up: unknown. There are no steps, because no dose-finding study has been done.

What the HHS policy says about dose

Nothing. As of November 2, 2026, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding KPV acetate in topical or oral forms, if ten conditions are met, until a final rule addresses KPV. Those conditions cover the ingredient’s identity and testing, a patient-specific prescription, a single active ingredient and adverse event reporting. An oral product also requires documentation of adequate oral bioavailability in humans, which is hard to square with FDA’s finding of no human absorption data. Injected KPV is not covered.

The policy is not an approval. KPV is not on the 503A bulks list, no rule has been proposed, and FDA has reviewed no compounded product for safety, effectiveness or quality. The notice says the policy is not binding, comments are open until November 13, 2026, HHS may revisit it if a safety signal or quality problem appears, it covers 503A compounding only, and states can be stricter. A prescriber who wrote for compounded KPV would be choosing an amount with no human data behind it, and a patient deserves to hear that directly.

Vial and syringe arithmetic

Online sellers offer KPV as a freeze-dried powder that the user mixes with bacteriostatic water, and FDA found injection promoted on websites. This section is here because math errors with vials can be large; it does not mean injecting KPV is supported, safe or covered by any policy. Our reconstitution guide covers the mechanics that apply to any peptide. The marks on an insulin syringe measure volume, so the water volume decides how much peptide each unit holds.

A worked example with a 5 mg vial, which is an illustration and not a fact about any product:

• 5 mg = 5,000 mcg. The vial holds that amount however much water is added.
• Add 2 mL: 5,000 mcg divided by 2 mL = 2,500 mcg per mL.
• A U-100 insulin syringe holds 100 units per mL, so 1 unit = 0.01 mL.
• 2,500 mcg per mL divided by 100 = 25 mcg per unit.

The table describes arithmetic, and we leave out dose columns on purpose because no KPV dose exists. The reconstitution calculator below does the same math for any vial and any volume, and the mg/mL to units converter works the other way round.

The errors that cost people most with vials:

• Mixing up mg and mcg. 1 mg is 1,000 mcg. A thousandfold error is one misplaced unit away.
• Reading units as micrograms. A unit is a hundredth of a milliliter. What it contains depends on the concentration.
• Copying someone else’s numbers. A unit count from a vial mixed with 1 mL is wrong for a vial mixed with 2 mL.
• Trusting the label on the vial. FDA found that “KPV” is not a standardized name and that different salts and derivatives are sold under it. A research-grade vial has no FDA-verified identity, potency or sterility, so even correct arithmetic rests on an unverified number.

The legal line for research vials

Products sold “for research use only” are not legal to use on people. The label comes from 21 CFR 312.160, which permits shipment only for laboratory animal or test-tube work, marked “Not for use in humans.” HHS says its October 2026 policy is meant to discourage this market, and the policy gives such products no cover. The KPV benefits page has the evidence behind each claim, and the FDA status tracker follows the rulemaking.